UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 5, 2010
BIOSCRIP, INC.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
0-28740
|
|
05-0489664 |
(State of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer |
|
|
|
|
Identification No.) |
|
|
|
100 Clearbrook Road, Elmsford, New York
|
|
10523 |
(Address of principal executive offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: (914) 460-1600
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
|
|
|
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
Item 7.01. |
|
Regulation FD Disclosure. |
BioScrip, Inc. (BioScrip) furnishes the information set forth in the slideshow presentation
attached hereto as Exhibit 99.1, the text of which is incorporated herein by reference.
The slideshow presentation includes certain non-GAAP financial measures as described therein. As
required by Regulation G, reconciliation between any non-GAAP financial measures presented and the
most directly comparable GAAP financial measures is also provided.
The information referenced in this Current Report on Form 8-K (including Exhibit 99.1 referenced in
Item 9.01 below) is being furnished under Item 7.01 Regulation FD Disclosure and, as such,
shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended, or otherwise subject to the liabilities of that Section and shall not be
incorporated by reference into any registration statement or other document filed by BioScrip
pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by
specific reference in such filing.
As discussed therein, the slideshow presentation contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the
intent, belief or current expectations of BioScrip, its directors, or its officers with respect to
the future operating performance of BioScrip. Investors are cautioned that any such
forward-looking statements are not guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from those in the forward-looking
statements as a result of various factors. Important factors that could cause such differences are
described in the Companys periodic filings with the Securities and Exchange Commission
BioScrip is scheduled to present at the BMO Capital Markets 10th Annual Focus on
Healthcare Conference, which is being held at the Sheraton New York Hotel & Towers, 811 7th Avenue
53rd Street, New York, New York, at 11:15 AM ET (Eastern Time). on Thursday, August 5, 2010. A
live audio web cast of BioScrips presentation will be available
online at www.bmocm.com/conferences/2010healthcare/webcast/ at 11:15 on the day of the
presentation and for a period of 30 days following the presentation. A web cast replay of the
presentation can also be accessed via BioScrips website at www.bioscrip.com, under the
Investors Section for a period of 30 days following the presentation.
|
|
|
Item 9.01 |
|
Financial Statements and Exhibits. |
(c) Exhibits
|
|
|
|
|
Exhibit No. |
|
Description of Exhibit |
|
99.1 |
|
|
Slideshow Presentation of BioScrip, Inc., dated April 5,
2010, at BMO Capital Markets Annual Focus on Healthcare
Conference |
2